Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Aug 9;103(32):e38879.
doi: 10.1097/MD.0000000000038879.

Real world study of GLP-1 receptor agonists in overweight or obese type 2 diabetes by using repeated measurement analysis of variance

Wanying Yang  1 , Xiangming Zhou  2 , Yuanyuan Miao  2 , Lu Wang  1 , Yunhui Zhao  1 , Tingyu Ke  2 , Lili Ban  1
Affiliations
Randomized Controlled Trial

Real world study of GLP-1 receptor agonists in overweight or obese type 2 diabetes by using repeated measurement analysis of variance

Wanying Yang et al. Medicine (Baltimore). .

Abstract

To investigate the safety and efficacy of long-acting glucagon like peptide-1 receptor agonists in overweight or obese patients with type 2 diabetes. Overweight or obese patients with type 2 diabetes from July 2021 to June 2022 were randomly divided into control group (metformin) and experimental group (metformin + dulaglitide or semaglutide). Repeated measures analysis of variance was used to compare Hemoglobin A1c, fasting plasma glucose and body mass index (BMI) of patients before treatment, 6 months and 12 months after treatment. The adverse reactions of patients before treatment and 12 months after treatment were analyzed. The time effect of Hemoglobin A1c, fasting plasma glucose and BMI in the control group (n = 35) and the experimental group (n = 32) were statistically significant (P < .001), and the intergroup effect of BMI was statistically significant (P < .05). The interaction effect of BMI was statistically significant (P < .001). The BMI level of the experimental group was lower than that of the control group at 6 and 12 months after treatment (P < .001). There was no significant difference in the incidence of adverse reactions between the 2 groups (P > .05). Long-acting glucagon like peptide-1 receptor agonists, such as dulaglitide and semaglutide, not only reduce glycosylated hemoglobin levels, but also significantly improve BMI in overweight or obese patients with type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1.
Figure 1.
HbA1c levels at different time points and interaction by group in the 2 groups. HbA1c = Hemoglobin A1c.
Figure 2
Figure 2
. BMI levels at different time points and interaction by group in the 2 groups. BMI = body mass index.
Figure 3.
Figure 3.
FPG levels at different time points and interaction by group in the 2 groups. FPG = fasting plasma glucose.
See this image and copyright information in PMC

References

    1. Diabetes Branch of Chinese Medical Association Chinese guidelines for the prevention and treatment of Type 2 Diabetes Mellitus (2020 Edition). Int J Endocrine Metab. 2021;41:482–548.
    1. Endocrinology Branch of Chinese Medical Association. Diabetes Branch of Chinese Medical Association Clinical expert consensus on the use of glucagon like peptide-1 (GLP-1) receptor agonist in the treatment of type 2 diabetes. Chin J Internal Med. 2020;59:836–46.
    1. Mei D. Clinical efficacy of dulaglutide injection in patients with type 2 diabetes mellitus with different body mass indexes. Chin Pract Med. 2023;18:127–30.
    1. Chen Z, Jing C, Fuming Y. Comparison of the efficacy of smeglutide and dagglinide combined with metformin in the treatment of newly diagnosed obese type 2 diabetes. Sino Foreign Med. 2023;42:125–8.
    1. Guoshuang F. Repeated measurement ANOVA and SPSS implementation. Chin J General Practitioners. 2017;16:740–2.

Publication types

MeSH terms